Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee

Phase 1

Active, not recruiting

• Conditions: Osteo Arthritis Knee; Degenerative Joint Disease of Knee
• Interventions: Biological: Autologous Adipose-Derived SVF (Stromal Vascular Fraction); Drug: Placebo

• Registration Number: NCT03940950
• Lead Sponsor: Mayo Clinic

Brief Summary

Researchers are trying to determine the safety and feasibility of autologous, adipose derived stromal vascular fraction injections in the treatment of knee osteoarthritis

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-05-06
• Study First Submitted QC: 2019-05-06
• Study First Posted: 2019-05-07
• Study Start: 2019-07-02
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-17
• Last Update Posted: 2025-01-20
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SVF (Stromal Vascular Fraction) Group	Autologous Adipose-Derived SVF (Stromal Vascular Fraction)	Subjects with knee osteoarthritis (OA) will receive Autologous Adipose-Derived SVF (Stromal Vascular Fraction) cells
Placebo Group	Placebo	Subjects with knee osteoarthritis (OA) will be treated with a placebo

Primary Outcome Measures

Name	Time	Method
Adverse Events	2 years	Number of adverse events reported

Trial Locations

Locations (1)

Mayo Clinic in Florida; 🇺🇸 Jacksonville, Florida, United States